Servier announces the success of its first private placement on the American market for $405M

23/07/2019

Paris, 23 July 2019 – Servier, an independent international pharmaceutical group, is announcing that it has successfully made an inaugural private placement for 405 million dollars on the US private placement (USPP) market, in four tranches with maturities of 7, 10, 12, and 15 years.

This first Servier private placement was enthusiastically welcomed by American investors and was very widely oversubscribed by more than four times, with a particularly long maturity of 12 and 15 years, highlighting the Group’s appeal and American investors’ confidence in the Group’s strategy, notably in the US.

This USPP is part of the refinancing of the syndicated loan set up in August 2018 for the acquisition of Shire’s oncology branch. This operation has enabled Servier to support its growth on the American market, where the Group is present through Servier Pharmaceuticals, its commercial subsidiary, and Servier BioInnovation.

“This first transaction on the US private placement market confirms investors’ confidence in Servier’s strategy and provides the Group with long-term foundations for financing in line with its development ambitions,” confirms Dominique Brissy, Senior Executive Vice-President Finance and Information Systems.

This first USPP enables the Group to diversify its sources of funding and to lengthen the average debt maturity.

Moving forward, Servier intends to make further use of this type of financing, enabling it to welcome on board long-term investors to support its business growth in France and around the world.

For this private placement, the Servier Group was supported by Société Générale.

 

 


 

About Servier
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.2 billion euros in 2018, Servier employs 22 000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generics) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.
More information: www.servier.com

 


Press contacts:
Sonia Marques : sonia.marques@servier.com – Tel. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13
Jean-Clément Vergeau : jean-clement.vergeau@servier.com – Tel. +33 (0)1 55 72 46 16 / + 33 (0) 6 79 56 75 96 Karine Bousseau : karine.bousseau@servier.com – Tel. +33 (0)1 55 72 60 37 / + 33 (0) 6 49 92 16 05

 


Disclaimer
This announcement is not an offer to sell or a solicitation of an offer to buy the securities mentioned herein in any jurisdiction.
The securities to which this announcement relates have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or with any securities regulatory authority of any state of the United States or other jurisdiction and may not be offered, sold, pledged or otherwise transferred in the United States except pursuant to registration or an exemption from the registration requirements of the Securities Act and in compliance with any applicable state securities laws.

Securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons unless they are registered under the Securities Act or an exemption from the registration requirements of the Securities Act is available. Any public offering of securities to be made in the United States or any other jurisdiction may only be made by means of a prospectus that may be obtained from the issuer or the selling security holder and that will contain detailed information about the company and management, as well as financial statements. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States.

This announcement is directed only at (a) persons who are outside the United Kingdom, (b) persons in the United Kingdom who have professional experience in matters related to investments and who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”), (c) high net worth entities falling within Article 49(2)(a) to (d) of the Order, and (d) other persons to whom it may be lawfully communicated (all such persons together being referred to as “relevant persons”). Any investment or investment activity to which this announcement relates is available only to, and will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents.